A study comparing pre-hospital administration of packed red blood cells and freeze-dried plasma with administration of normal saline in patients with low blood pressure after major injuries
| ISRCTN | ISRCTN62326938 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN62326938 |
| Clinical Trials Information System (CTIS) | 2015-001401-13 |
| Protocol serial number | 31157 |
| Sponsor | University Hospitals Birmingham NHS Foundation Trust |
| Funder | National Institute for Health Research |
- Submission date
- 11/07/2016
- Registration date
- 11/07/2016
- Last edited
- 02/09/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Injury, Occupational Diseases, Poisoning
Plain English summary of protocol
Background and study aims
Major trauma accounts for a significant number of deaths worldwide, and is one of the most frequent causes of death in people under the age of 40. A large number of these deaths are caused by major bleeding as a result of the trauma (traumatic haemorrhage). Patients with traumatic heamorrhage are currently given clear fluids but military and civilian research suggests that survival increases if hospital patients receive blood products (red blood cells and freeze-dried plasma) instead. The best treatment for bleeding patients before reaching hospital is uncertain. Giving too much fluid to improve blood pressure can increase bleeding. Therefore only small amounts of clear fluid are given. Some pre-hospital doctors now give red blood cells instead. Animal research suggests that this is better than clear fluids, and that adding plasma is better still. Some studies in humans support this however other research has found no benefit. There is currently no good quality evidence exists to show whether giving blood products before hospital, saves lives. The aim of this study is to find out whether giving blood products to badly injured adult patients, before reaching hospital improves their clinical condition and survival.
Who can participate?
Patients believed to be over the age of 16 who have sustained a serious injury leading to major blood loss.
What does the study involve?
Participants are randomly allocated to one of two groups at the scene of the emergency. Those in the first group receive fluids through a drip, with up to four bags of normal saline (salt water). Those in the second group receive two units of concentrated red blood cells and two units of freeze dried plasma (straw like fluid that makes up the liquid part of blood). Participants in both groups are followed up for 30 days to find out if any patients died (of their injuries or otherwise), as well as the speed they are able to clear lactic acid from their tissues (indicator of good blood flow). Blood pressure, heart rate, blood clotting and whether patients need organ support are also monitored while they are on intensive care.
What are the possible benefits and risks of participating?
There are no guaranteed direct benefits involved with participating in this study however the blood product treatment could be shown to be more effective than standard treatment. There are no notable risks involves for those participating in this study.
Where is the study run from?
Pre-hospital emergency medicine and major trauma centres in the West Midlands, Dorset & Somerset and in the East of England (UK)
When is the study starting and how long is it expected to run for?
October 2015 to April 2020
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Miss Gemma Slinn, rephill@trials.bham.ac.uk
Contact information
Public
Birmingham Clinical Trials Unit
University of Birmingham
Birmingham
B15 2TT
United Kingdom
| Phone | +44 121 415 9100 |
|---|---|
| rephill@trials.bham.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised; Interventional; Design type: Treatment, Drug |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A multicentre randomised controlled trial of prehospital blood product administration versus standard care for traumatic haemorrhage |
| Study acronym | RePHILL |
| Study objectives | The aim of this study is to investigate whether giving blood products (red blood cells and freeze-dried plasma) to badly injured adult patients, before reaching hospital improves their clinical condition and survival. |
| Ethics approval(s) | South Central - Oxford C Research Ethics Committee, 15/12/2015, ref: 15/SC/0691 |
| Health condition(s) or problem(s) studied | Traumatic haemorrhage |
| Intervention | Participants are randomised in a 1:1 ratio to receive: Crystalloid resuscitation: Consisting of up to 4 x 250 mL bags of 0.9% sodium chloride (normal saline). These will be administered as boluses of 250 mL to maintain a radial pulse Pre-Hospital Blood Products (BHBP) resuscitation: Consisting of up to 2 units of PRBC and 2 units of LyoPlas. These will be administered as boluses consisting of a single unit of blood product, given in the sequence: PHBP, LyoPlas, PHBP, LyoPlas. LyoPlas N-w is a freeze dried plasma product derived from a single donation and is licenced for use in the same indication as fresh frozen plasma. LyoPlas N-w is licensed for use in Germany as a medicinal product under the Marketing Authorisation Number PEI.H.03075.01.1. PRBC are a concentrated preparation of red blood cells that is obtained from whole blood by removing the plasma (as by centrifugation). The PRBC used in RePHILL will be blood group O, RhD negative, Kell negative from NHS Blood and Transplant national stocks supplied by the blood banks that are supporting this trial. Patients receive the trial interventions on-scene, because of the emergency nature of this trial, patients are considered randomised when the transport box containing the interventions is opened. Follow-up will comprise of standard care follow-up for patients that have a traumatic injury, no further trial-specific procedures will be undertaken after the delivery of the interventions but we will collect data pertaining to the RePHILL outcome measures for up to 30 days post-injury. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. 1. Episode mortality is measured by whether or not the patient is still alive up to 30 days post injury up to 30 days post injury |
| Key secondary outcome measure(s) |
1. All-cause mortality rate is measured by whether or not the patient is still alive within 3 hours of randomisation |
| Completion date | 31/05/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 490 |
| Total final enrolment | 432 |
| Key inclusion criteria | 1. Traumatic injury 2. Pre-Hospital Emergency Medical team attend 3. Hypotension (SBP <90mmHg or absence of palpable radial pulse) believed to be due to traumatic haemorrhage |
| Key exclusion criteria | 1. Children (known or apparently aged <16 years) 2. Refusal of blood product administration; known Jehovah’s Witness 3. Pregnancy (known or apparent) 4. Isolated head injury |
| Date of first enrolment | 01/10/2016 |
| Date of final enrolment | 31/12/2020 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centres
Mindelsohn Way
Birmingham
B15 2WB
United Kingdom
Millennium Point
Waterfront Business Park
Waterfront Way
Brierley Hill
DY5 1LX
United Kingdom
Hawthorn House
Dudley Road
Stourbridge
DY9 8BQ
United Kingdom
Hazell House
Burnthurst Lane
Princethorpe
CV23 9QA
United Kingdom
Brindley Way
Wakefield 41 Business Park
Wakefield
WF2 0XQ
United Kingdom
10 South Lane
Elland
HX5 0HQ
United Kingdom
Whiting Way
Melbourn
Melbourn
SG8 6EN
United Kingdom
St. Mary's Street
Huntingdon
PE29 3PE
United Kingdom
Gambling Close
Norwich Airport
Norwich
NR6 6EG
United Kingdom
Flight House
Earls Colne Business Centre
Earls Colne Business Park
Earls Colne
Colchester
CO6 2NS
United Kingdom
1 Horizon Place
Mellors Way
Nottingham Business Park
Nottingham
NG8 6PY
United Kingdom
Belper
DE56 1PX
United Kingdom
Hazell House
Burnthurst Lane
Princethorpe
CV23 9QA
United Kingdom
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
Newcastle Road
Stoke-on-Trent
ST4 6QG
United Kingdom
Southmead Road
Westbury-on-Trym
Bristol
BS10 5NB
United Kingdom
Great George Street
Leeds
LS1 3EX
United Kingdom
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
Anlaby Road
Hull
HU3 2JZ
United Kingdom
Herries Road
Sheffield
S5 7AU
United Kingdom
Cambridge Biomedical Campus
Hills Road
Cambridge
CB2 0QQ
United Kingdom
Colney Lane
Norwich
NR4 7UY
United Kingdom
Derby Road
Nottingham
NG7 2UH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available Previous participant exclusion criteria: Planned publication in a high-impact peer reviewed journal. A protocol paper will be published within the next six months. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 04/03/2022 | 11/03/2022 | Yes | No | |
| Results article | 01/01/2024 | 02/09/2024 | Yes | No | |
| Protocol article | protocol | 01/10/2018 | 06/03/2020 | Yes | No |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
02/09/2024: Publication reference added.
11/03/2022: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the reference.
26/10/2020: The public contact's details have been changed and the plain English summary updated accordingly.
06/03/2020: The following changes have been made:
1. Publication reference added.
2. The publication and dissemination plan has been updated.
3. The intention to publish date has been changed from 30/04/2021 to 31/05/2022.
10/02/2020: The following changes have been made:
1. The recruitment end date has been changed from 31/01/2020 to 31/12/2020.
2. The overall trial end date has been changed from 30/04/2020 to 31/05/2021.
3. The trial website has been added.
02/04/2019: The condition has been changed from "Specialty: Injuries and emergencies, Primary sub-specialty: Injuries and emergencies; UKCRC code/ Disease: Injuries/ Certain early complications of trauma" to "Traumatic haemorrhage" following a request from the NIHR.
18/07/2016: Verified study status with principal investigator.